[1]Sharp A, Bhosle J, Abdelraouf F, et al. Development of molecularly targeted agents and immunotherapies in small cell lung cancer[J]. Eur J Cancer, 2016, 60:26-39.
[2]Carter BW, Glisson BS, Truong MT, et al. Small cell lung carcinoma: staging, imaging, and treatment considerations[J]. Radiographics, 2014, 34(6):1707-1721.
[3]Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? -a review[J]. Transl Lung Cancer Res, 2016, 5(1):26-38.
[4]Hassan WA, Yoshida R, Kudoh S, et al. Evaluation of role of Notch3 signaling pathway in human lung cancer cells[J]. J Cancer Res Clin Oncol, 2016, 142(5):981-993.
[5]Zhang JX, Han YP, Bai C, et al. Notch1/3 and p53/p21 are a potential therapeutic target for APS-induced apoptosis in non-small cell lung carcinoma cell lines[J]. Int J Clin Exp Med, 2015, 8(8):12539-12547.
[6]Hassan WA, Yoshida R, Kudoh S, et al. Evaluation of role of Notch3 signaling pathway in human lung cancer cells[J]. J Cancer Res Clin Oncol, 2016, 142(5):981-993.
[7]Yuan X, Wu H, Xu H, et al. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis[J]. Sci Rep, 2015, 5:10338.
[8]Shi C, Qian J, Ma M, et al. Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients[J]. Cell Physiol Biochem, 2014, 34(3):743-752.
[9]Ou WB, Zhu J, Eilers G, et al. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status[J]. Oncotarget, 2015, 6(12):10510-10520.
[10]Zhu Y, Regunath K, Jacq X, et al. Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry[J]. Genes Dev, 2013, 27(16):1739-1751.
[11]Yu H, Zou Y, Jiang L, et al. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles[J]. Biomaterials, 2013, 34(11):2738-2747.
[12]Künkele A, De Preter K, Heukamp L, et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas[J]. Neuro Oncol, 2012, 14(7):859-869.
[13]Park C, Jeong JS, Jeong JW, et al. Ethanol extract of Kalopanax septemlobus leaf inhibits HepG2 human hepatocellular carcinoma cell proliferation via inducing cell cycle arrest at G1 phase[J]. Asian Pac J Trop Med, 2016, 9(4):344-350.
[14]Hu H, Dong Z, Tan P, et al. Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner[J]. Oncotarget, 2016, 7(3):3171-3185.
[15]Li JP,Cai ShZh, Liu J, et al. Replicative senescence characteristics of human leukemia cell line (K562) induced by ginsenoside Rg1[J]. Acta Anatomica Sinica, 2012, 43(4):473-478.(in Chinese)
李建平, 蔡世忠, 刘俊, 等. 人参皂苷Rg1诱导人白血病K562细胞复制性衰老的机制[J]. 解剖学报, 2012, 43(4):473-478.
[16]Bhattacharya S, Ghosh MK. HAUSP, a novel deubiquitinase for Rb-MDM2 the critical regulator[J]. FEBS J, 2014, 281(13):3061-3078.
[17]Inoue K, Fry EA, Frazier DP. Transcription factors that interact with p53 and Mdm2[J]. Int J Cancer, 2016, 138(7):1577-1585.
[18]Zhou R, Lu Z, Liu K, et al. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo[J]. Curr Cancer Drug Targets, 2015, 14(9):860-871.
[19]Giovannini C, Minguzzi M, Baglioni M, et al. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma[J]. Oncotarget, 2014, 5(21):10607-10620.
[20]Kim D, Song J, Jin EJ. MicroRNA-221 regulates chondrogenic differentiation through promoting proteosomal degradation of slug by targeting Mdm2[J]. J Biol Chem, 2010, 285(35):26900-26907.
|